The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts  by Paglino, Justin & Tattersall, Peter
Virology 416 (2011) 32–41
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roThe parvoviral capsid controls an intracellular phase of infection essential for
efﬁcient killing of stepwise-transformed human ﬁbroblasts
Justin Paglino a, Peter Tattersall a,b,⁎
a Department of Laboratory Medicine, Yale University Medical School, 333 Cedar Street, New Haven, CT 06520, USA
b Department of Genetics, Yale University Medical School, 333 Cedar Street, New Haven, CT 06520, USA⁎ Corresponding author at: Department of Laborato
Medical School, 333 Cedar Street, New Haven, CT 06520
E-mail address: peter.tattersall@yale.edu (P. Tattersa
0042-6822/$ – see front matter © 2011 Elsevier Inc. Al
doi:10.1016/j.virol.2011.04.015a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 February 2011
Returned to author for revision 1 April 2011
Accepted 25 April 2011
Available online 20 May 2011
Keywords:
LuIII








Stepwise transformationMembers of the rodent subgroup of the genus Parvovirus exhibit lytic replication and spread in many human
tumor cells and are therefore attractive candidates for oncolytic virotherapy. However, the signiﬁcant
variation in tumor tropism observed for these viruses remains largely unexplained. We report here that LuIII
kills BJ-ELR 'stepwise-transformed' human ﬁbroblasts efﬁciently, while MVM does not. Using viral chimeras,
we mapped this property to the LuIII capsid gene, VP2, which is necessary and sufﬁcient to confer the killer
phenotype on MVM. LuIII VP2 facilitates a post-entry, pre-DNA-ampliﬁcation step early in the life cycle,
suggesting the existence of an intracellular moiety whose efﬁcient interaction with the incoming capsid shell
is critical to infection. Thus targeting of human cancers of different tissue-type origins will require use of
parvoviruses with capsids that effectively make this critical interaction.ry Medicine, Yale University
, USA. Fax: +1 203 688 7340.
ll).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Members of the rodent subgroup of genus Parvovirus, including H-1,
LuIII, and Minute Virus of Mice (MVM), are potential candidates for
oncolytic virotherapy of human cancer for several reasons. Firstly, these
viruses are naturally S-phase dependent, so that they preferentially
target host cell populations that are proliferating, while sparing those
that are not. The rodent parvoviruses are also markedly oncoselective,
displaying enhanced ﬁtness and toxicity in many human cancer cell
lines compared to their untransformed counterparts, although they
show variable tropism between tumor types (Chen et al., 1986; Chen
et al., 1989; Cornelis et al., 2004; Dupont et al., 2000; Guetta et al., 1990;
Legrand et al., 1992; Mousset et al., 1994; Rommelaere and Cornelis,
1991; Van Hille et al., 1989). They show potent oncosuppressive
properties in many in vivo models, including syngeneic mouse tumor
models and human xenografts transplanted into immunocompromised
animals (Dupressoir et al., 1989; Faisst et al., 1998; Raykov et al., 2007;
Rommelaere and Cornelis, 1991; Shi et al., 1997; Toolan, 1967; Toolan
et al., 1982), and can also induce both curative and protective immune
responses in some immunocompetent rodent tumor models (Guetta
et al., 1986; Geletneky et al., 2010). Importantly for the prospective useof these agents in virotherapy of human cancer, there is no human
disease associated with any known member of this genus (Dupont,
2003; Rommelaere and Cornelis, 1991; Siegl, 1984). Finally, the small
diameter of these viruses, approximately 20–25 nm, may facilitate
intra-tumoral virion spread (Everts and van der Poel, 2005; Wu et al.,
2001), while their rugged virion structure would allow them to survive
protracted storage with minimal loss of potency.
In the present study we ﬁrst illustrate that different parvovirus
species vary in their ability to grow in and kill particular cells, and that
different transformed human cells are variably susceptibility to virus-
mediated killing, thus presenting hurdles for the rational targeting of
human cancers. In order to further study this aspect of parvoviral target
cell speciﬁcity, we have examined parvoviral oncoselectivity in
stepwise-transformed human cells. In this approach, normal primary
human cells are rendered tumorigenic in nude mice by the sequential
retroviral transduction of transforming genes (Hahn and Weinberg,
2002), potentially allowing dissection of the contributions of individual
oncogenes to speciﬁc steps in the parvoviral life cycle. Here we use one
of the best characterized of these model systems (Hahn et al., 1999) to
show that untransformed human ﬁbroblasts are resistant to killing by a
panel of rodent sub-group parvoviruses, but that the fully-transformed
derivative, while still resistant to most of these viruses, is efﬁciently
killedby theorphanparvovirus LuIII. This propertymaps to the LuIII coat
protein gene, the product of which plays a critical role early in the
establishment of infection of these transformed cells.
Fig. 1. Killing of transformed and normal human cells by a panel of ﬁve parvoviruses.
Panel A: SV40-transformed new-born human kidney cells, NB324K, were seeded in 24-well
plates at lowdensity and infected atdifferentmultiplicitieswithgenome-titeredpuriﬁedviral
stocks of representative isolates of different species of Parvovirus, as indicated. Monolayers
were incubated, ﬁxed and stained as described in Materials and methods. The right-hand
column represents the normal cell control (NCC). Panel B: HeLa cervical carcinoma cells;
Panel C:BJ humanﬁbroblasts; andPanelD: stepwise-transformedBJ-ELR (BJ+hTERT+SVER
(LT+ST)+Ras) cells, respectively, were analyzed for viral killing as described for panel A.
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Rodent parvoviruses exhibit different host ranges in transformed human
cells
In order to screen for themost effective virus:host cell combinations,
we used a multi-well plate assay to monitor infection by a panel of ﬁve
representative virus species that cluster phylogenetically with the
rodent viruseswithin the genus Parvovirus. These include the prototype
strain of the murine virus, MVMp, the two rat viruses H1 and H3 (the
latter also known as Kilham Rat Virus), and two viruses of unknown
animal origin, LuIII and TVX, originally isolated as contaminants of
human cell lines (Hallauer et al., 1972). The viruses were grown in cell
culture, puriﬁed and their genome concentrations determined by
Southern blotting of alkaline gels probed with a conserved sequence
oligonucleotide. Rapidly proliferating, sub-conﬂuent monolayer cul-
tures of cells in 24well plates were infected at different input levels and
stained for surviving cells 6 days post infection. This assay monitors
several facets of viral infection, including acute killing at high
multiplicity of infection (moi), as well as the virus' ability to proliferate
and spread through the culturewhen infection is initiated at lower virus
inputs. As shown in Fig. 1A, four of the viruses, MVMp, LuIII, H1 and H3
efﬁciently killed NB324K cells, while TVX had no detectable effect, even
at highmoi. In contrast,MVMphad no effect inHeLa cells, even at a high
input level, while TVX completely destroyed the monolayer, even
when infection was initiated at the lowest input multiplicity tested
(32 genomes per cell, Fig. 1B). Since NB324K are papovavirus SV40-
transformed newborn kidney cell line, whereas HeLa cells are derived
from a papillomavirus-initiated cervical carcinoma, these two trans-
formed human cell lines differ in many ways.
Complete stepwise oncogenic transformation of human ﬁbroblasts
dramatically enhances killing by parvovirus LuIII
Since it was unclear whether the differences in response to the
parvovirus panel were due to the genetics of the host or tissue type, the
nature of the transforming virus, or to stochastic differences that have
arisen during transformation, we decided to examine the requirements
for rodent parvovirus infection of transformed human cells in a more
controlled fashion. To do this we tested the same panel of viruses for
their ability to kill BJ primary human ﬁbroblasts and their tumorigenic
derivative, BJ-ELR, which were transformed by stepwise-addition of
hTERT, the SV40 Early Region (SVER, which expresses both Large T
Antigen (LT) and Small T Antigen (ST), and the activated proto-
oncogeneRasV12 (Hahnet al., 1999). As shown in Fig. 1C, noneof theﬁve
viruses had a detectable effect on the growth of the parental
untransformed BJ cells at any of the input mois tested (up to 1000
genomes per cell). In contrast, two of the ﬁve viruses had pronounced
effects on the survival of BJ-ELR monolayers (Fig. 1D). One of these, H1,
only hadobservable effects at thehighest inputmois, but the other, LuIII,
efﬁciently killed themajority of transformed cells down toan inputof 64
genomes per cell, which represents a 16-fold lower initial moi than the
maximum tested in this assay. Thus LuIII, and to a lesser extent by H1,
are oncoselective for growth and killing in human ﬁbroblasts since their
infectivities are speciﬁcally enhanced by cellular alterations that drive
oncogenesis.We also tested the lymphotropic strain ofMVM,MVMi, for
its ability to kill BJ-ELR, as well as three other MVM strains isolated as
contaminants of commercial product streams (Garnick, 1996), but these
all proved ineffective, indicating that BJ ﬁbroblasts express a block to
growth of MVM that is circumvented by LuIII.
Growth of MVM and LuIII are both enhanced by transformation, but only
LuIII can expand effectively in transformed BJ cells
To better understand the phenotypes of MVMp and LuIII observed
in the killing assay, we used an expansion assay, which measures the
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assay compares the fraction of cells that are positive for viral NS1
antigen at 24 and 72 hours post infection (hpi) in rapidly growing
cultures initially infected at low moi. As shown in Fig. 2A, the
expansion index of MVM in BJ cells was signiﬁcantly less than one
(0.3±0.04), indicating that the percentage of cells infected decreasedover time, consistent with little or no progeny virus production.
By comparison (pb0.005), an expansion index of approximately 1.0
(1.4±0.7) for MVM in BJ-ELR suggested it was able to produce
sufﬁcient progeny to maintain a “balanced” or “persistent” infection,
in which the percentage of cells infected remains relatively
unchanged over time as the culture itself expands. In fact we found
this to be the case, and were able to passage an MVM-infected culture
of BJ-ELR for over 20 population doublings while the percentage of
infected cells remained between 0% and 2% (data not shown). Thus
MVMp does exhibit modest oncoselectivity in this assay, but even
complete transformation does not remove all blocks to viral
expansion. In contrast, LuIII has an expansion index of 1.1±0.07
even in BJ cells, showing that it is better adapted to untransformed
human ﬁbroblasts than MVMp (pb0.005). Moreover, the addition of
hTERT, SVER, and Ras raises the expansion index for LuIII by a further
50-fold (59±12), clearly demonstrating that oncogenic transforma-
tion of human ﬁbroblasts enables LuIII to expand efﬁciently through
the culture. As might be expected, the expansion indices for all four
virus:cell pairs correlate well with the previously observed efﬁcien-
cies of killing, since an expansion index signiﬁcantly greater than one
would be necessary to kill an entire culture of growing cells initially
infected at a low moi.
The expansion data show that both viruses are oncoselective to a
certain degree in this model system, but that MVMp is disadvantaged
compared to LuIII in BJ cells, regardless of their transformation status.
To ask whether early viral life cycle events are responsible for these
differences, we compared their initiation efﬁciencies in an assay that
measures the overall efﬁcacy of the early steps in infection, including
binding, entry, endosomal escape, nuclear trafﬁcking, uncoating, and
NS1 expression. As seen in Fig. 2, while initiation frequencies for LuIII
appeared very similar in both cell types, we observed a 2.9-fold
(±1.5) initiation advantage for LuIII over MVM in BJ (Fig. 2B), and 1.7-
fold (±0.5) advantage for LuIII in BJ-ELR (Fig. 2C). Thus, LuIII exhibits
a distinct advantage over MVM in initiating infection of both normal
and transformed lines, but whether this difference alone is enough to
explain the dramatic disparity between the killing effects of the two
viruses in BJ-ELR cells required further examination.
The VP2 ORF of LuIII promotes efﬁcient killing of BJ-ELR by an MVM-LuIII
chimera
Next we used viral genomic chimeras to ask whether there was a
single region of LuIII that could confer its killing phenotype on MVMp.
These recombinants shufﬂed fourmajor sectionsof thegenome, the left-
hand hairpin, the NS coding region, the VP coding region, and the right-
handhairpin, between LuIII andMVMpasdiagrammed in Fig. 3A,where
M or L in the virus name denotes the origin of each segment in order
along the genome. In addition,we generated LuCap, which contains just
the VP2 gene of LuIII in theMVMpbackbone. Fig. 3B shows the results of
killing assays performed in BJ-ELR with these viruses. The MLLM
recombinant showed the same killing efﬁciency as LuIII, indicating that
the hairpins of LuIII confer no advantage over those of MVM in this cell
line. The MMLM chimera was 3–4 fold less efﬁcient at killing than LuIII,Fig. 2. Infection parameters of MVM and LuIII in BJ and BJ-ELR. Panel A: The ability of
each virus to expand within each cell line was measured in spot slides cultures of BJ or
BJ-ELR, infected at low multiplicity with MVM or LuIII. Parallel slides were ﬁxed at 24
hpi and 72 hpi and assessed for NS1 expression by ﬂuorescent antibody staining. The
fraction of NS1-positive cells at 72 h was divided by the fraction positive at 24 h to
calculate the expansion index for MVM and LuIII in BJ cells (light gray bars) and BJ-ELR
cells (unﬁlled bars). Data points represent average values from two independent
experiments and error bars represent a single standard deviation in either direction.
Initiation efﬁciencies for MVM (–■–) and LuIII (–●–) are shown in Panel B for BJ cells
and in Panel C for BJ-LER cells. The cells were infected over a range of multiplicities with
MVM or LuIII, incubated in medium with neuraminidase until 24 hpi, and then ﬁxed
and assayed for NS1 expression by immunoﬂuorescence microscopy. Data points
represent the average value from two independent experiments, and error bars
represent a single standard deviation in each direction.
Fig. 3. Killing of BJ-ELR by chimeric viruses. Panel A shows a map of genomic features
common to MVM and LuIII, showing hairpins, promoters, major ORFs, and the 3′ UTR.
The location of restriction sites used to generate chimeras between LuIII and MVM are
indicated. MVM, LuIII, and chimeras MLLM,MLMM,MMLM, and LuCap are diagrammed
to indicate the origin of each section of the genome. Panel B shows killing assays for the
chimeras and their parents in BJ-ELR cells, performed as described for Fig. 1.
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cell; an input that was determined by initiation assays (not shown) to
result in the initial infection of ~10% of BJ-ELR cells. These ﬁndings,
together with an observed expansion index for MMLM of 50 (not
shown), support the contention that the region spanning the VP gene
cassette is sufﬁcient for productive infection of BJ-ELR cultures. The
further 3–4 fold increase in efﬁciency seen for MLLM suggests that the
NS region of LuIII provides an incremental advantage over that of MVM
in BJ-ELR, but that this advantage is not necessary for productive and
lytic growth. Conversely, the NS-spanning region of LuIII alone is not
sufﬁcient to confer the expansion phenotype in BJ-ELR, as demonstrated
by the MLMM virus, which was indistinguishable in this assay from
MVMp (Fig. 3B).
As shown in Fig. 3A, the VP gene in MMLM includes not only the
LuIII VP2 gene, but also the LuIII VP1-speciﬁc region, which, inMVM, is
responsible for several essential functions in viral entry (Farr et al.,
2005). In addition this region contains the 3′ UTR, for which no
distinct function has yet been established. However, these regions of
LuIII do not signiﬁcantly contribute to expansion in BJ-ELR cells, since
the LuCap chimera exhibits the same killing phenotype as MMLM
(Fig. 3B), indicating that the LuIII VP2 ORF alone is sufﬁcient to
overcome the signiﬁcant block to growth encountered by MVMp in
these transformed cells. This ﬁnding allowed us to use many of the
genetic and serological tools that we had already developed for MVM
to analyze the role of the LuIII VP2 in dramatically facilitating
parvoviral infection of these stepwise transformed human ﬁbroblasts.
Use of differential qPCR to detect small differences in viral ﬁtness
Next we attempted to measure the contribution of LuIII VP2 to
initial event(s) in the viral life cycle by comparing MVMp with LuCapusing the initiation assay. While this assay conﬁrmed that LuCap had
an advantage over MVMp in BJ-ELR, the difference was relatively
minor, as observed previously for the parental viruses (Fig. 2). This
raised the concern that errors inherent in side-by-side comparison of
separate infections might be confounding, and suggested that an
internally controlled method of comparing the two viruses would be
required to test their relative ﬁtness in a sufﬁciently exact way. The
strategy we adopted was to co-infect cells with an equimolar mixture
of two viruses containing differently marked genomes, and then
compare the ratios of each co-infecting genome at several time points
by differential qPCR. Determining the ratio of the two genomes in any
particular sample reduces inaccuracies, since both would be subject
equally to any errors in dilution, processing, or sampling for PCR, as
well as differences between individual infected cell cultures.
To allow multiplex qPCR measurements of genome ratio, we
constructed LuAlt, a phenocopy of LuCap with eight silent mutations
in its MVMp-derived NS1 ORF, as shown in Fig. 4A. LuAlt was designed
to serve as a competitor for either MVMp, in experimental co-
infections, or LuCap in control co-infections. In this differential assay,
the mutated region of LuAlt binds a VIC ﬂuorophore-labeled probe
termed “alternate,” whereas the wildtype sequence in this region of
MVMp or LuCap binds a FAM-labeled probe, designated “standard.”
Using common outside primers and real-time qPCR, we validated the
assay by measuring LuCap genomes alone, LuAlt genomes alone, or
equimolar mixtures of LuCap and LuAlt genomes. Fig. 4B and C shows
the strong correlation (r=−0.999 in both cases) between genomes
per reaction and Ct observed for both probes over a ﬁve log10 range,
from 103 to 108 genomes per reaction. Both probes were highly
speciﬁc, as each failed to generate signal above the Ct threshold after
45 cycles in a reaction with 108 copies of the non-targeted sequence.
To check that the overall replicative efﬁciency of LuAlt was the
same as LuCap, we performed a co-infection over multiple rounds of
viral growth, in order to allow any ﬁtness difference between the co-
infecting/competing viruses to compound over time. Accordingly, low
density BJ-ELR cultures were infected with an equimolar mixture of
LuCap and LuAlt, or an equimolar mixture of MVM and LuAlt,
representing a total input moi of 40 genomes per cell, sufﬁcient to
infect approximately 1% of cells initially, and passaged as described in
the Materials and methods. After each of two passages, the relative
genome concentrations were determined by qPCR and expressed as
“Fraction Standard” (Fs), calculated as described in Materials and
methods. As shown in Fig. 4D, there was no signiﬁcant change in this
parameter over one or two passages for co-infections of Lu-Cap and
LuAlt. This result indicated that the eight single base differences
between the two genomes conferred no particular advantage on
either virus over 6 days of multiple-cycle growth, allowing us to use
co-infections withMVMp and LuAlt to explore the difference in ﬁtness
between viruses conferred by the VP2-ORF alone. As shown in Fig. 4D,
LuAlt extensively outgrew MVM after one multiple-cycle passage, as
would be expected from the killing assay and expansion data.
Speciﬁcally, after the ﬁrst passage the MVMp standard virus
represented just ~9% of progeny virus, and after the second passage
only 0.5%, indicating that the VP2 ORF of LuIII confers a signiﬁcant
advantage for some aspect(s) of viral replication in BJ-ELR cells.
The LuIII capsid does not enhance receptor binding, entry, or occlusion in
BJ-ELR
The multiplex qPCR assay also provided a sensitive tool for
exploring early steps in the life cycle that might potentially be
enhanced by delivering the viral genome in LuIII VP2 capsids. For this
BJ-ELR were co-infected at high multiplicity with either of the two
mixed inocula, LuCap (standard) plus LuAlt, or MVMp (standard) plus
LuAlt, and cells and medium harvested at 4 and 6 hpi. Samples were
then digested with micrococcal nuclease to remove unencapsidated
viral DNA, and analyzed by qPCR. Fig. 5A shows Fs values for input
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hpi. As expected, the Fs for the LuCap versus LuAlt control co-infection
remained unchanged from the input value in both the cell extract and
the medium. Signiﬁcantly, the same result was observed for the
MVMp versus LuAlt combination. Because there was no signiﬁcant
decrease seen in Fs for either the cell extract or the post-adsorption
medium, we conclude that genomes encapsidated in either VP2 shell
become cell-associated with the same efﬁciency over the 4-h
incubation, during which time approximately 25% of each virus
inoculum attached to the cells.
Following the initial incubation step, a parallel culture was
incubated for two more hours in fresh medium containing neuramin-
idase, allowing time for viral receptor cleavage and the removal of
surface-bound virions. Virus that remained cell-associated at 6 hpi,
following neuraminidase treatment, was characterized as “occluded,”and comprised the sum of virions inside endosomes, those that had
escaped from that compartment into the cytosol and were en route to
the nucleus, and those in the nucleus. Occluded virus at 6 hpi
represented approximately 85% of the virus that was cell-associated at
4 hpi, suggesting that most cell-associated virus had already been
internalized by the cell at 4 hpi, and also that little of this was recycled
back on to the cell surface during the next 2 h. As expected, the Fs for
the LuCap plus LuAlt control co-infection remained unchanged from
the input value in both the cell extract and the medium, as shown in
Fig. 5B. Once again, however, we saw a similar result for the MVMp
plus LuAlt co-infection. Because there was still no decline in Fs in the
cell extract or increase in Fs in the medium by 6 hpi, we conclude that
the kinetics of occlusion are essentially identical for genomes
contained in capsids of MVM or LuIII origin.
The LuIII VP2 ORF facilitates a step prior to viral genome ampliﬁcation
We next wished to examine whether LuIII VP2 confers an
advantage at an early post-entry step of the viral life cycle, such as
escape from the endosome, trafﬁcking to the nucleus or uncoating.
However, the high particle-to-infectivity ratios required for these
experiments and the low efﬁciency of endosomal escape rendered it
impossible for us to identify productive routes of infection using the
qPCR assay. Accordingly, we restricted our analysis of these events to
monitoring subsequent DNA ampliﬁcation, using differential qPCR to
measure viral DNA replication during a co-infection conducted under
one step growth conditions. Low molecular weight DNA was
extracted from co-infected cells at 6, 24 and 48 hpi using the method
of Hirt (Hirt, 1967), which isolates replicative form (RF) DNA
molecules and releases single-stranded genomes from progeny
virions. For the 24 and 48 hpi samples, which contain signiﬁcant
amounts of RF as well as progeny DNA, we took the further step of
individually separating and isolating the duplex 5 kbp monomer and
10 kbp dimer RFs by agarose gel electrophoresis and gel extraction.
The Southern blot of a parallel agarose gel (Fig. 6A) shows these
predominant 5 kb and 10 kb viral RF DNA species in the 24- and 48-h
Hirt extracts. A longer exposure of this blot also revealed a single-
stranded progeny form that co-migrated with single-stranded DNA
from occluded input genomes in the 6-h Hirt extract. Fs values were
determined for the 6-h Hirt extract, as well as for the 5 and 10 kb gel
extracts at 24 hpi and 48 hpi, and results are shown in Fig. 6B.
As expected, no signiﬁcant change in Fs was observed in any
sample from the LuCap vs LuAlt co-infection. In contrast, MVM
sequences represented only ~10% of 5Kb and 10Kb forms in the
MVMp plus LuAlt co-infection extracted at 24 hpi, down from 50% of
occluded genomes in the 6 hpi extract. The under-representation ofFig. 4. Relative ﬁtness analysis using differential qPCR. Panel A. Positive strand
nucleotides 436–459 within the NS gene of wildtype MVMp, and thus of LuCap (see
Fig. 3), are shown above the eight single base changes introduced to create LuCap-Alt.
Oligonucleotide probes for discriminating between these two “standard” and
“alternate” sequences are diagrammed, labeled with FAM and VIC ﬂuorophores,
respectively. Both probes bear the TAMRA quencher at their 3′ ends, which is separated
from the ﬂuorophore at the 5' end of bound probe by the endonuclease activity of the
TaqMan® polymerase during the PCR reaction. Panels B and C show quantitation of
standard and alternate genomes, respectively, over a range of concentrations, as
indicated, using Taq-Man real-time PCR, either alone (❍) or in an equimolar mixture
with the other genome type (♦). Ct value represents the PCR cycle at which ﬂuorescent
signal from the ﬂuorophore crossed a set threshold value. Panel D shows relative ﬁtness
determinations for LuCap-Alt versus either LuCap or MVMp standard virions. BJ-ELR
were co-infected at low multiplicity with either LuCap or MVM mixed with LuCap-Alt
virus at an approximately equimolar ratio, as determined by Southern blot analysis.
Initial Fs values were determined from a sample of each inoculum by qPCR (unﬁlled
bars). After 72 h of multi-step co-culture, total progeny virus was analyzed by qPCR, as
described in Materials and methods, and the Fs for the ﬁrst passage determined (gray
bars). These samples were then used to infect another set of cultures, which were
processed as before, and the Fs after the second passage calculated (black bars). Data
points for Fs represent the average of two separate plates, each one assayed in duplicate,
and error bars represent one standard deviation in either direction.
Fig. 6. DNA replication in coinfected cells. BJ-ELR were co-infected at high multiplicity
with equimolar mixtures of LuCap-Alt with either LuCap and MVM standard viruses, as
before. Cell samples from 4, 6, 24, and 48 hpi were processed for small molecular weight
DNA by Hirt extract as described in Materials and methods, where neuraminidase was
present from 4 h onwards. Panel A shows an image of the ethidium stained gel
overlayed with the autoradiograph of a Southern blot of the same gel probed for viral
DNA. In the lanes containing the 24 and 48 h samples, boxes represent the regions of a
parallel gel from which DNA was extracted. Panel B shows Fs values determined by
qPCR for 6 h Hirt extract, tested directly (unﬁlled bars), 5 kb (gray bars) or 10 kb
species (black bars), extracted from gel slices for 24 or 48 h samples, as indicated. Data
points represent the average of at least three qPCR measurements, and error bars
indicate one standard deviation in either direction.
Fig. 5. Binding and entry/occlusion. BJ-ELR were co-infected at highmultiplicity with an
equimolar mix of LuCap-Alt and standard LuCap or MVMp viruses. Panel A shows initial
Fs values determined from the inoculum as described in Fig. 4 (unﬁlled bars). After 4r h
of incubation, unattached (gray bars) and cell-associated virions (black bars) were
isolated as described in Materials and methods, and their Fs values determined by
differential qPCR. At the same time, the medium on a set of parallel plates was replaced
with medium containing neuraminidase, to remove viral receptors, and cultures
incubated for an additional 2 h. Panel B shows Fs values determined for detached or
recycled encapsulated genomes (gray bars) and cell-associated, or occluded, virions
(black bars), at 6 hpi. Data points represent an average value from two separate plates,
and error bars represent one standard deviation in either direction.
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reﬂect either a block between occlusion and initiation of MVM DNA
replication, or slower MVMp genome ampliﬁcation, compared to that
of LuAlt. To look for differences in kinetics of DNA ampliﬁcation
between the two viruses, we compared the Fs values for 5Kb and 10Kb
RF at 24 and 48 hpi. No signiﬁcant decrease in Fs value for either RF
species was observed over that time period, indicating that, onceinitiated, DNA ampliﬁcation continues with the same kinetics for both
viruses. Thus it appears likely that the diminished Fs observed at 24 h
is due to a VP2-dependent difference in the two viral life cycles that
occurs at or before the onset of DNA ampliﬁcation, either at the stage
of endosomal escape, nuclear trafﬁcking, virion uncoating, early gene
expression, or the initiation of effective replication complexes.
LuIII VP2 confers no signiﬁcant advantage for progeny single-stranded
DNA synthesis or post-replication events
The parvoviral VP2 N-terminus is known to be involved in nuclear
export in some cell lines (Maroto et al., 2004), and certainly the
efﬁciency of capsid assembly, packaging and release from the cell
might differ between different capsid proteins, providing additional
potential advantages for LuIII VP2 later in the lifecycle. In order to test
for differences in these later events between the two viruses, we
measured Fs for encapsidated progeny genomes at 24 and 48 h, both
in cell extracts and in the medium. Fig. 7 shows that 24 h after an
equimolar MVM plus LuAlt co-infection, approximately 10% of
progeny genomes are MVM, both in the cells and in the medium.
These Fs values are not signiﬁcantly different from those measured for
viral RF at the same time point, indicating that there is no difference in
the kinetics of progeny genome packaging attributable to the
disparate VP2s. This is corroborated by the ﬁnding that at 48 h there
is no diminution in Fs from that seen at 24 h, showing that indeed
Fig. 7. Progeny production and export. BJ-ELRwere co-infected at highmultiplicity with
equimolar mixtures of LuCap-Alt with either LuCap and MVM standard viruses, as
before. Cells and medium were harvested at 6 hpi, 24 hpi, and 48 hpi, processed and
analyzed by qPCR to determine Fs values for encapsidated genomes for the 6-h occluded
virus sample (unﬁlled bars), and for either cell-associated progeny virus (gray bars), or
progeny virions released into the medium (black bars), at 24 or 48 hpi, as indicated.
Data points represent the average values from at least two separate plates, and error
bars represent one standard deviation in either direction.
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Additionally, since we did not observe any relative increase in Fs for
progeny in the cell extract versus progeny in the medium, either at 24
or 48 h, we conclude that LuIII VP2 does not confer an advantage for
virion export from the cell. The possibility also exists that MVMp
genomes could be trans-encapsidated into LuIII VP2 capsids in co-
infected cells, thereby masking a possible defect in downstream
packaging or export for MVMp VP2 capsids. However, based on the
initiation data shown in Fig. 2B, we estimate that a signiﬁcantmajority
of infected cells were singly-infected, rather than co-infected, at the
multiplicities used. Thus it is unlikely that trans-encapsidation could
obscure a packaging or export defect of any magnitude.
Discussion
Stepwise models of human cellular oncogenic transformation,
such as that originally described by Hahn and Weinberg (2002) offer
clear advantages for studying parvoviral oncoselectivity. The trans-
formed human cells are directly derived from their normal precursor
by deﬁned steps, and each of these can be studied individually for
their contribution to parvoviral growth. However, initial efforts to
study the oncoselectivity of MVM in this cell systemwere confounded
by the inefﬁciency of MVMp replication and killing in the stepwise
transformed cells, which was surprising since this virus grows well in
a variety of human cell lines, particularly in 324 K, newborn kidney
cells transformed with SV40. The study of adeno-associated virus
(AAV) vectors over the past decade or more has demonstrated that
different AAV serotypes showed dramatically different abilities to
transduce therapeutic or reporter genes into cells of different human
or murine tissue types (Arruda and Xiao, 2007; Van Vliet et al., 2008).
In the family Parvoviridae, serotype is a major deﬁning component of
species, so that different serotypes within the genus Dependovirus are
considered separate species, and isolates of the same species within
the genus Parvovirus are highly related serologically, but antigenically
quite distinct from isolates of other species (Tattersall et al., 2005).
This consideration prompted us to screen strains derived from dif-ferent Parvovirus species for their ability to expand in and kill BJ-ELR
cultures, resulting in the identiﬁcation of LuIII as the oncolytic virus of
choice for these cells.
The advantage of LuIII over MVMp is observed in both normal and
transformed human ﬁbroblasts, suggesting that the underlying
mechanism is a consequence of the differentiation phenotype of the
host cell, rather than LuIII being intrinsically more oncoselective than
MVM. The differential qPCR approach provided accurate comparison
of the efﬁciency with which each virus completes certain individual
steps in the infectious process, and allowed us to narrow down the
LuIII advantage to a step between endosomal escape and the initiation
of viral DNA replication. This result resembles a cell culture model of
parvoviral tissue tropism that our laboratory has studied for several
years. MVMp and MVMi, two strains of the same Parvovirus species,
are reciprocally restricted for growth in each other's host cell types,
ﬁbroblasts and T-lymphocytes, respectively (Tattersall and Bratton,
1983). In ﬁbroblasts, MVMi initiates NS1 expression with 5–10 fold
lower efﬁciency than MVMp, indicative of an early life cycle block
(Ball-Goodrich and Tattersall, 1992) and MVMp is similarly restricted
in lymphocytes. MVMp and MVMi, however, reciprocally compete for
binding to receptors on the surface of each other's host cell (Spalholz
and Tattersall, 1983), suggesting that the point of restriction is at a
subsequent, probably intracellular, step. Mapping of the ﬁbrotropic
determinant through the use of inter-strain recombinants identiﬁed
two amino acid substitutions in the VP2 of MVMi, at positions 317 and
321, are sufﬁcient to increase this strain's infectivity in ﬁbroblasts to
that of MVMp (Gardiner and Tattersall, 1988b), which in turn allows
overall replication in ﬁbroblasts to reach an level of efﬁciency
approaching that of MVMp (Ball-Goodrich and Tattersall, 1992).
Subsequently, several pairs of amino acid changes that coordinately
switched the tropism of MVMi were mapped to residues lining the
depression at the capsid two-fold symmetry axis (Agbandje-McKenna
et al., 1998), a region that has been dubbed the 'allotropic determinant',
and that corresponds to the capsid glycan-binding pocket (Nam et al.,
2006).
Previsani et al. (1997) reported that input genomes of MVMi and
MVMp3, an MVMi chimera carrying the MVMp allotropic determi-
nant, reached the nuclear compartment of EL4 T-lymphocytes with
similar efﬁciency and kinetics to MVMp, but that MVMp3 subse-
quently exhibited a major defect in the timing and extent of viral DNA
ampliﬁcation. Later steps in the viral life cycle were not affected by the
origin of the allotropic determinant, since transfection of infectious
clones of either MVMp or MVMi into either host cell resulted in
equivalent single round infectious cycles (Gardiner and Tattersall,
1988a; Previsani et al., 1997), leading to the suggestion that the
allotropic determinant region of the capsid interacts with an
intracellular factor that catalyzes an essential early event in the viral
life cycle, such as endosomal escape, nuclear trafﬁcking, or uncoating,
although the ﬁnding of similar kinetics in nuclear transport favor a
post-nuclear-entry step, perhaps uncoating. The robust reciprocal
blocks to growth of MVM strains in each other's host cell therefore
appears to mirror the block to MVMp capsid-mediated infection of
stepwise transformed human ﬁbroblasts we report here. The
molecular mechanism controlling tropism in both cases is unclear,
but at least in the case of LuCap and MVM, there appears to be
competition between viruses in cells co-infected at high input
multiplicity, to the speciﬁc disadvantage of MVMp (data not
shown), suggesting that the VP2 of LuIII has a higher afﬁnity than
that of MVMp for an unidentiﬁed intracellular factor, or “co-receptor.”
In this scenario, the interaction of the capsid with this co-receptor
might take place in the endosome, the cytosol, or the nucleus, and
would play an essential role in a critical local event. Signiﬁcantly, the
NS1 expression advantage for LuIII over MVMp is only 1.7-fold in BJ-
ELR (Fig. 2C), whereas LuAlt replicative DNA is approximately 5-fold
more abundant than is that of MVMp at 24 and 48 hpi (Fig. 6B). This
might argue in favor of the critical step enhanced by LuIII VP2
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experiments exploring these early stages of the infectious process will
be required to exact step(s) at which the LuIII VP2 advantage is
executed.
An alternative explanation for the advantage conferred by the LuIII
capsid is that a nucleotide element within the VP2 gene determines
tropism, rather than the gene product itself. Although this possibility
is not formally ruled out by the data presented here, it seems unlikely
since trans-encapsidation experiments performed by others have
identiﬁed the capsid protein proper as determinative of parvoviral
tropism in other human cell types (Wrzesinski et al., 2003; Maxwell
et al., 1995).
The sequence of LuIII VP2 differs from that of MVMp at 170 amino
acid residues, representing ~30% of the protein. Approximately one
third of these differences are conservative and, by comparison with the
known structure of MVMp, the great majority of them are predicted to
be on the viral surface. Interestingly, homology drops to less than 50%
across the two regions that form a cleft at the icosahedral two-fold axes
to which the MVM allotropic determinant maps. Analysis of further
intragenic VP2 recombinants will be required to establish if structural
features within this two-fold cleft are also responsible for the capsid-
mediated restriction described here. Nam et al. (2006) have suggested
that differences in glycan-binding speciﬁcity of the pocket at the capsid
2-fold cleft deﬁne the allotropic phenotypes ofMVMpandMVMi. Such a
mechanism may also underlie the differential target cell speciﬁcity
reportedhere, however differences between the glycan-bindingproﬁles
of MVMp and LuIII remain to be explored, as does the putative role of
interactions between the capsid and cellular glycans in determining the
efﬁciency of establishing infection in human cells by these rodent
parvoviruses.
Infection by both MVMp and LuIII is augmented by stepwise
oncogenic transformation, consistent with multiple previous demon-
strations of parvoviral oncoselectivity. That oncogenes hTERT, LT, ST,
and Ras collectively enhance the parvoviral lifecycle opens the
possibility of using this, or similar models, to explore the contribution
of individual oncogenes to parvoviral growth in human cells. However,
despite the facilitating effect of stepwise transformation for both LuIII
andMVMp, the latter remains substantially blocked for efﬁcient growth
in fully transformed human BJ ﬁbroblasts. We postulate that the
characteristic enhancement of parvoviral growth by transformation can
be effectively “trumped” by the target cell's differentiation phenotype.
Effective targeting of human tumorswill, therefore, depend on selection
of a VP2 for the vector that is appropriate for targeting the tissue of
origin for each particular tumor. Thus, future attempts to identify
appropriate parvoviral capsids for different human tumors will likely
parallel the many previous studies that have revealed a pivotal role for
AAV serotype in the effective targeting of AAV-based gene therapy
vectors (Arruda and Xiao, 2007; Van Vliet et al., 2008).
Materials and methods
Cells
Normal primary diploid human foreskin ﬁbroblasts BJ were
obtained from the ATCC (Manassas, VA). BJ-ELR (BJ+TERT, Ras,
SVER) were the kind gift of Dr. Robert Weinberg (Whitehead Institute
for Biomedical Research). All cells were grown in Dulbecco's Modiﬁed
Eagle's Medium (DMEM) containing 10% fetal bovine serum, non-
essential amino acids, sodium pyruvate, glutamine, penicillin, and
streptomycin.
Infection initiation assay
4000 BJ or BJ-ELR were seeded on Teﬂon-coated glass spot-slides,
incubated overnight at 37 °C, and infected with virus at the indicated
inputs for 2 h. The inoculum was then exchanged for growth mediumcontaining 0.1 μg/ml neuraminidase. Slides were ﬁxed and stained for
NS1 at 24 hpi, as described previously (Farr and Tattersall, 2004).
Expansion assay
2500 BJ or BJ-ELR were seeded on glass spots on Teﬂon coated
spot-slides, incubated overnight at 37 °C, and infected at 100 genomes
per cell for 2 h at 37 °C. The inoculum was then replaced with 100 μL
of growth medium and incubated at 37 °C. Separate slides were ﬁxed
and stained for NS1 at 24 and 72 hpi, as previously described (Farr and
Tattersall, 2004).
Viral constructs
pdBMVp, an infectious clone of MVMp, was described previously
(Cotmore and Tattersall, 1992). pLU1Nde, an infectious clone of LuIII,
and pMLLM were described previously (Cotmore and Tattersall,
2005). pMMLM was generated by exchanging the 2954 nt NarI–AatII
fragment of pdBMVp for that of pMLLM. pMLMM was generated by
exchanging the 2942 nt NarI–AatII fragment of pMLLM for that of
pdBMVp.
To generate pSac-Pac, the precursor to pLuCap, a silent PacI site was
engineered at the end of the VP2ORF of pdBMVp-Sac, a previously
constructedderivativeof pdBMVpwith a silent SacI site at the beginning
of the VP2 ORF (Farr et al., 2006). To generate pLuCap, the VP2 ORF of
LuIII was PCR ampliﬁed with mutagenic primers introducing a PacI site
(LUPAC5′-G CA T AG T T AA T T AA T AAG TG T T T C T AG C-3′) at the
endof the VP2ORF and a SacI site (LUSAC2 5′-G C TG CGCAGCAGAG
C T C T C A G A C A A T-3′) at the beginning of the VP2 ORF (restriction
sites underlined). The PCR productwas digestedwith SacI and PacI, gel-
puriﬁed, and cloned into pre-digested pdBMVp-Sac-Pac, and the entire
insert sequenced in both directions. pLuAlt was generated using two-
step PCR mutagenesis, using overlapping central primers to introduce
eight sequential silent third-position codonmutations in theNS1ORF of
pLuCap, as described in Fig. 4A.
Killing assay
10,000 cells were seeded in a volume of 800 μL per well in 24-well
plates and incubated overnight. 200 μL of inoculum of the appropriate
dilution was then added to each well. After 6 days of incubation at
37 °C, the monolayers were visualized by staining with Leishman's
solution. Images were processed, as a group, in Adobe Photoshop.
Real-time multiplex qPCR
Primers and probes for qPCR were designed using Primer Express®
software and employed TaqMan® technology (Applied Biosystems,
Foster City, CA). Fluorescent probes were purchased from Applied
Biosystems. “Standard” and “Alternate” probe designs are illustrated in
Fig. 4A. Probeswere added toeach reactionat250 nM. PCRampliﬁcation
was accomplishedwith outside primers OKFW5′-G C A G G A GG A C G
AGCTGAAAT-3′ andOKRV5′-C CCATTCCATGTCCTCGC-3′, each
at 900 nM. PCR reactions were performed and analyzed using the
Applied Biosystems PRISM® 7900 Sequence Detection System instru-
ment and software, in accordance with the manufacturer's recommen-
dations. Standards, consisting of serial 10-fold dilutions equimolar
mixtures of “standard” and “alternate” taggedgenomes inplasmid form,
ranging from 103 to 108 genomes per reaction, were included in
duplicate in each run of PCR, and separate standard curves were
generated for FAM and VIC ﬂuorescence. All samples were measured in
duplicate. The “Fraction Standard” (Fs), is the fraction of total genomes
in a sample that are standard, as determined by qPCR, and calculated as
follows: Fs=[Std]/([Std]+[Alt]) where [Std]=measured concentra-
tion of standard genomes, and [Alt]=measured concentration of
alternate genomes.
40 J. Paglino, P. Tattersall / Virology 416 (2011) 32–41Measurement of encapsidated genomes by qPCR
A 20 μL aliquot of each sample was made 10 mM Tris–HCl, pH 8.0,
and 6 mM CaCl2, then digested for 1 h at 37 °C with 0.4 mg/mL
micrococcal nuclease. EGTA was added to 15 mM to chelate calcium
ions and inactivate the nuclease. Samples were then diluted at least
1:100 in TES buffer (1 mM Tris–HCl pH 8.0, 0.1 mM EDTA, 10 μg/mL
salmon sperm DNA) before adding 5 μL to a 50 μL qPCR reaction.
This protocol was tested by measuring the genome concentration
of plasmid DNA or puriﬁed virus, either following straight dilution in
TES, or after performing the assay described abovewith orwithout the
addition of nuclease. There was no signiﬁcant difference in measured
genome concentration for puriﬁed virus under any of these con-
ditions, showing that neither the buffer alone nor digestion with
nuclease have any effect on accurate measurement of encapsidated
genomes. However, while measured plasmid DNA concentration was
unaffected by the addition of buffer alone, it was reduced ~10,000 fold
in the presence of nuclease.
Measuring encapsidated genomes following multiple- or single-round
co-infections
For multiple-round co-infections (performed in the absence of
neuraminidase), 100 mm culture disheswere seededwith 300,000 BJ-
ELR each, and incubated overnight at 37 °C. Medium was replaced
with 900 μL of inoculum containing an equimolar mixture of standard
and alternate viruses, each at a concentration of 20 genomes per cell.
Plates were incubated at 37 °C for 2 h, then the inoculumwas replaced
with 10 mL growth medium. At 72 hpi the cells were scraped into the
medium, collected by centrifugation, resuspended in TE8.7 and
subjected to three freeze–thaw cycles to extract the virus. For each
plate, 10% of cell extract was combined with 10% of the supernatant
for qPCR analysis, along with a sample of inoculum, as described
above. For the second passage of competition, the cell extract/
supernatant mixtures generated and measured in the ﬁrst passage
were used as inocula, diluted to a total encapsidated genome
concentration of 40 genomes per cell, and treated as before.
For single round coinfections, 35 mm diameter plates were seeded
with 100,000 BJ-ELR, incubated overnight at 37 °C, then infected with
200 μL of inoculum containing an equimolar mixture of standard and
alternate virus, each at 1000 genomes per cell and incubated at 37 °C.
At 4 hpi, one set of plates was harvested, and medium on all other
plates was changed to 200 μL of medium containing neuraminidase at
0.1 mg/mL to cleave off viral receptor. At 6 hpi, another set of plates
was harvested, and medium on the remaining plates changed to 2 mL
of medium containing neuraminidase. These plates were incubated at
37 °C before being harvested at 24 hpi or 48 hpi as described above,
except that medium supernatants and cell extracts were analyzed
separately.
Analysis of replicative-form DNA
250,000 BJ-ELR were seeded in 60 mm dishes, incubated overnight
at 37 °C, then coinfected, under single-round conditions, at 1000
genomes per cell of each virus. Pelleted cells were harvested in 100 μL
of Hirt Wash Buffer (20 mM Tris, 150 mM NaCl, 10 mM EDTA), and
replicative form DNA isolated by a modiﬁcation of the method of Hirt
extraction as described previously (Tattersall et al., 1973), and half of
each sample electrophoresed in a 1.4% agarose gel. For the 24 and 48
hpi samples, gel slices from the 5 kb and 10 kb region of each lane
were processed with the QIAquick® Gel Extraction Kit (Qiagen) into
30 μL of 10 mM Tris pH 8.0. 5 μL of each these extracts, in addition to
5 μL of the 6 hpi DNA extract, were directly analyzed by qPCR. The
remaining half of each sample was electrophoresed on a separate gel,
which was ethidium-stained, photographed, and analyzed by South-
ern blot using a 32P-labeled probe generated from the PmlI–NarI (NS1region) fragment of MVM using a Random Primed DNA Labeling Kit
(Roche, Indianapolis, IN). An image of the ethidium-stained gel was
overlaid in Adobe Photoshop with an image of the Southern blot
autoradiograph by aligning vertical and horizontal markers within
each.
Statistical analysis
Expansion indices were compared by t Test, using KaleideGraph
software v3.6 (Synergy Software) after logarithmic conversion of data
(x'=log(x+1)) as recommended for statistical analysis of ratios
(Ryder and Robakiewicz, 2001).
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